Double dose vs. standard dose influenza vaccination in patients with heart failure: A pilot study

Amy Van Ermen, Matthew P. Hermanson, John M. Moran, Nancy K Sweitzer, Maryl R. Johnson, Orly Vardeny

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

AimsInfluenza infection leads to increased morbidity and mortality in those with heart failure, and individuals with heart failure exhibit reduced antibody responses to influenza vaccine. We hypothesized that patients with heart failure randomized to double dose (DD) influenza vaccine will mount more vigorous humoral immune responses compared with those given standard dose (SD) vaccine.Methods and resultsWe randomized 28 heart failure patients to DD (30 μg/strain) or SD (15 μg/strain) influenza vaccine. We assessed antibody production by haemagglutination inhibition assay (reported as log haemagglutination units) prior to, at 2-4 weeks and at 4-6 months following vaccination. Baseline antibody titres between DD (n = 12, mean age 64 ± 10 years) and SD (n = 16, mean age 63 ± 9 years) did not differ significantly. At 2-4 weeks, DD haemagglutination unit changes were significantly higher than those of SD (3.3 vs. 1.6 for A/H3N2, P < 0.001; 1.9 and 1.1 for A/H1N1, P = 0.009; and 1.7 and 1 for B-type, P = 0.02). At 4-6 weeks, there were no differences in titres in any of the virus types between treatment groups and, although titres decreased, levels remained above the seroprotective threshold.ConclusionsHigher influenza vaccine doses may elicit increased antibody-mediated responses in patients with heart failure; further studies should assess whether clinical outcomes are improved with this strategy. All rights reserved.

Original languageEnglish (US)
Pages (from-to)560-564
Number of pages5
JournalEuropean Journal of Heart Failure
Volume15
Issue number5
DOIs
StatePublished - May 2013
Externally publishedYes

Fingerprint

Human Influenza
Influenza Vaccines
Vaccination
Heart Failure
Hemagglutination
Antibody Formation
Humoral Immunity
Vaccines
Viruses
Morbidity
Mortality
Antibodies
Infection
Therapeutics

Keywords

  • Heart failure
  • Immune system
  • Influenza vaccine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Double dose vs. standard dose influenza vaccination in patients with heart failure : A pilot study. / Van Ermen, Amy; Hermanson, Matthew P.; Moran, John M.; Sweitzer, Nancy K; Johnson, Maryl R.; Vardeny, Orly.

In: European Journal of Heart Failure, Vol. 15, No. 5, 05.2013, p. 560-564.

Research output: Contribution to journalArticle

Van Ermen, Amy ; Hermanson, Matthew P. ; Moran, John M. ; Sweitzer, Nancy K ; Johnson, Maryl R. ; Vardeny, Orly. / Double dose vs. standard dose influenza vaccination in patients with heart failure : A pilot study. In: European Journal of Heart Failure. 2013 ; Vol. 15, No. 5. pp. 560-564.
@article{faa89b62073a429283020f1a10072ae0,
title = "Double dose vs. standard dose influenza vaccination in patients with heart failure: A pilot study",
abstract = "AimsInfluenza infection leads to increased morbidity and mortality in those with heart failure, and individuals with heart failure exhibit reduced antibody responses to influenza vaccine. We hypothesized that patients with heart failure randomized to double dose (DD) influenza vaccine will mount more vigorous humoral immune responses compared with those given standard dose (SD) vaccine.Methods and resultsWe randomized 28 heart failure patients to DD (30 μg/strain) or SD (15 μg/strain) influenza vaccine. We assessed antibody production by haemagglutination inhibition assay (reported as log haemagglutination units) prior to, at 2-4 weeks and at 4-6 months following vaccination. Baseline antibody titres between DD (n = 12, mean age 64 ± 10 years) and SD (n = 16, mean age 63 ± 9 years) did not differ significantly. At 2-4 weeks, DD haemagglutination unit changes were significantly higher than those of SD (3.3 vs. 1.6 for A/H3N2, P < 0.001; 1.9 and 1.1 for A/H1N1, P = 0.009; and 1.7 and 1 for B-type, P = 0.02). At 4-6 weeks, there were no differences in titres in any of the virus types between treatment groups and, although titres decreased, levels remained above the seroprotective threshold.ConclusionsHigher influenza vaccine doses may elicit increased antibody-mediated responses in patients with heart failure; further studies should assess whether clinical outcomes are improved with this strategy. All rights reserved.",
keywords = "Heart failure, Immune system, Influenza vaccine",
author = "{Van Ermen}, Amy and Hermanson, {Matthew P.} and Moran, {John M.} and Sweitzer, {Nancy K} and Johnson, {Maryl R.} and Orly Vardeny",
year = "2013",
month = "5",
doi = "10.1093/eurjhf/hfs207",
language = "English (US)",
volume = "15",
pages = "560--564",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Double dose vs. standard dose influenza vaccination in patients with heart failure

T2 - A pilot study

AU - Van Ermen, Amy

AU - Hermanson, Matthew P.

AU - Moran, John M.

AU - Sweitzer, Nancy K

AU - Johnson, Maryl R.

AU - Vardeny, Orly

PY - 2013/5

Y1 - 2013/5

N2 - AimsInfluenza infection leads to increased morbidity and mortality in those with heart failure, and individuals with heart failure exhibit reduced antibody responses to influenza vaccine. We hypothesized that patients with heart failure randomized to double dose (DD) influenza vaccine will mount more vigorous humoral immune responses compared with those given standard dose (SD) vaccine.Methods and resultsWe randomized 28 heart failure patients to DD (30 μg/strain) or SD (15 μg/strain) influenza vaccine. We assessed antibody production by haemagglutination inhibition assay (reported as log haemagglutination units) prior to, at 2-4 weeks and at 4-6 months following vaccination. Baseline antibody titres between DD (n = 12, mean age 64 ± 10 years) and SD (n = 16, mean age 63 ± 9 years) did not differ significantly. At 2-4 weeks, DD haemagglutination unit changes were significantly higher than those of SD (3.3 vs. 1.6 for A/H3N2, P < 0.001; 1.9 and 1.1 for A/H1N1, P = 0.009; and 1.7 and 1 for B-type, P = 0.02). At 4-6 weeks, there were no differences in titres in any of the virus types between treatment groups and, although titres decreased, levels remained above the seroprotective threshold.ConclusionsHigher influenza vaccine doses may elicit increased antibody-mediated responses in patients with heart failure; further studies should assess whether clinical outcomes are improved with this strategy. All rights reserved.

AB - AimsInfluenza infection leads to increased morbidity and mortality in those with heart failure, and individuals with heart failure exhibit reduced antibody responses to influenza vaccine. We hypothesized that patients with heart failure randomized to double dose (DD) influenza vaccine will mount more vigorous humoral immune responses compared with those given standard dose (SD) vaccine.Methods and resultsWe randomized 28 heart failure patients to DD (30 μg/strain) or SD (15 μg/strain) influenza vaccine. We assessed antibody production by haemagglutination inhibition assay (reported as log haemagglutination units) prior to, at 2-4 weeks and at 4-6 months following vaccination. Baseline antibody titres between DD (n = 12, mean age 64 ± 10 years) and SD (n = 16, mean age 63 ± 9 years) did not differ significantly. At 2-4 weeks, DD haemagglutination unit changes were significantly higher than those of SD (3.3 vs. 1.6 for A/H3N2, P < 0.001; 1.9 and 1.1 for A/H1N1, P = 0.009; and 1.7 and 1 for B-type, P = 0.02). At 4-6 weeks, there were no differences in titres in any of the virus types between treatment groups and, although titres decreased, levels remained above the seroprotective threshold.ConclusionsHigher influenza vaccine doses may elicit increased antibody-mediated responses in patients with heart failure; further studies should assess whether clinical outcomes are improved with this strategy. All rights reserved.

KW - Heart failure

KW - Immune system

KW - Influenza vaccine

UR - http://www.scopus.com/inward/record.url?scp=84877155153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877155153&partnerID=8YFLogxK

U2 - 10.1093/eurjhf/hfs207

DO - 10.1093/eurjhf/hfs207

M3 - Article

C2 - 23291729

AN - SCOPUS:84877155153

VL - 15

SP - 560

EP - 564

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 5

ER -